跳到正文
原文
HUTCHMED· @hutchmed · X·· 12 小时前精选AI 评分62
AI 导读

和黄医药宣布,NMPA已同时批准SYVIK®(sovleplenib)用于原发免疫性血小板减少症(ITP)和温抗体型自身免疫性溶血性贫血(wAIHA)。该药是中国首个获批的新型Syk抑制剂,也是和黄医药在肿瘤之外首个实现商业化的免疫领域药物。

推荐理由

原文给出该药在中国获批的两项适应症及首创属性,读者可据此了解其在免疫领域的定位。

正文

We are proud to announce that China’s NMPA has granted simultaneous approval for SYVIK® (sovleplenib)—the first novel Syk inhibitor approved in China—for primary ITP and wAIHA, marking our first commercialized immunology drug beyond oncology. https://www.hutch-med.com/sovleplenib-china-approval/

来源:HUTCHMED · x.com